These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 34894256)

  • 1. Clinical significance of HScore and MS score comparison in the prognostic evaluation of anti-MDA5-positive patients with dermatomyositis and interstitial lung disease.
    Zhao S; Ma X; Zhang X; Jin Z; Hu W; Hua B; Wang H; Feng X; Sun L; Chen Z
    Mod Rheumatol; 2022 Feb; 32(2):373-379. PubMed ID: 34894256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
    Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
    J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.
    Sakamoto S; Okamoto M; Kaieda S; Fujimoto K; Nagata S; Tominaga M; Nakamura M; Zaizen Y; Nouno T; Koga T; Kawayama T; Kuwana M; Ida H; Hoshino T
    Respir Investig; 2018 Nov; 56(6):464-472. PubMed ID: 30150008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical characteristics and prognostic factors of patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis associated interstitial lung disease].
    Zou RY; Zhao Q; Tian YQ; Yan X; Qiu XH; Gao YJ; Liu Y; Huang M; Cao M; Dai JH; Cai HR
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Aug; 46(8):781-790. PubMed ID: 37536988
    [No Abstract]   [Full Text] [Related]  

  • 5. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
    Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
    Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
    Ye Y; Fu Q; Wang R; Guo Q; Bao C
    J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics and prognostic implications of peripheral blood lymphocyte subsets in patients with anti-MDA5 antibody positive dermatomyositis-interstitial lung disease.
    Ren FP; Chen Q; Yao SS; Feng L; Xue XY; Zhao WC; Wang D; Zhao ZL; Gu SW; Li T; Shen YW; Gao L; Zang XL; Bao XY; Tong ZH
    BMC Pulm Med; 2023 Oct; 23(1):411. PubMed ID: 37898737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic evaluation of serum osteopontin in patients with anti-MDA5 antibody-positive dermatomyositis associated interstitial lung disease.
    Gao Y; Zhao Q; Xie M; Yan X; Li Y; Zhang X; Wu H; Dai J; Cao M; Cai H
    Cytokine; 2020 Nov; 135():155209. PubMed ID: 32738770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.
    Motegi SI; Sekiguchi A; Toki S; Kishi C; Endo Y; Yasuda M; Ikeuchi H; Sakairi T; Hara K; Yamaguchi K; Maeno T; Hiromura K; Ishikawa O
    Eur J Dermatol; 2019 Oct; 29(5):511-517. PubMed ID: 31617496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokeratin 19 fragment is associated with severity and poor prognosis of interstitial lung disease in anti-MDA5 antibody-positive dermatomyositis.
    Gui X; Ma M; Ding J; Shi S; Xin X; Qiu X; Zhang Y; Qiu Y; Cao M; Huang M; Cao M; Dai J; Cai H; Xiao Y
    Rheumatology (Oxford); 2021 Aug; 60(8):3913-3922. PubMed ID: 33501503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble CD206 levels correlate with disease deterioration and predict prognosis of anti-MDA5 antibody-positive dermatomyositis related interstitial lung disease.
    Li Y; Liu X; Tian M; Zou R; Gao Y; Huang M; Zhou K; Cao M; Cai H
    Clin Respir J; 2023 Jun; 17(6):507-515. PubMed ID: 37041007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical characteristics of subcutaneous and mediastinal emphysema in anti-melanoma differentiation-associated 5 positive dermatomyositis associated with interstitial lung disease.
    Huang W; Chen D; Ren F; Luo L; Zhou J; Huang D; Tian M; Qian K; Jiang Y; Tang L
    Clin Exp Rheumatol; 2024 Feb; 42(2):262-268. PubMed ID: 38147317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD.
    Horiike Y; Suzuki Y; Fujisawa T; Yasui H; Karayama M; Hozumi H; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Ogawa N; Suda T
    Rheumatology (Oxford); 2019 Dec; 58(12):2143-2152. PubMed ID: 31143953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for mortality in patients with anti-MDA5 antibody-positive dermatomyositis: A meta-analysis and systematic review.
    Xie H; Zhang D; Wang Y; Shi Y; Yuan Y; Wang L; Fan J; Tian X; Wang J
    Semin Arthritis Rheum; 2023 Oct; 62():152231. PubMed ID: 37348186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of biomarkers in anti-MDA5-positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease.
    Li X; Liu Y; Cheng L; Huang Y; Yan S; Li H; Zhan H; Li Y
    J Clin Lab Anal; 2022 Nov; 36(11):e24726. PubMed ID: 36221983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis.
    Zuo Y; Ye L; Liu M; Li S; Liu W; Chen F; Lu X; Gordon P; Wang G; Shu X
    Rheumatology (Oxford); 2020 Oct; 59(10):2829-2837. PubMed ID: 32065646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis.
    Gono T; Kawaguchi Y; Satoh T; Kuwana M; Katsumata Y; Takagi K; Masuda I; Tochimoto A; Baba S; Okamoto Y; Ota Y; Yamanaka H
    Rheumatology (Oxford); 2010 Sep; 49(9):1713-9. PubMed ID: 20498012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation and validation of the prognostic value of anti-MDA5 IgG subclasses in dermatomyositis-associated interstitial lung disease.
    Xu YT; Zhang YM; Yang HX; Ye LF; Chen F; Lu X; Wang GC; Peng QL
    Rheumatology (Oxford); 2022 Dec; 62(1):397-406. PubMed ID: 35412602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis.
    So J; So H; Wong VT; Ho R; Wu TY; Wong PC; Tam LH; Ho C; Lam TT; Chung YK; Li WL; To CH; Lau CS; Mok CC; Tam LS
    Rheumatology (Oxford); 2022 Nov; 61(11):4437-4444. PubMed ID: 35157042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gender differences in patients with anti-MDA5-positive dermatomyositis: a cohort study of 251 cases.
    Cheng L; Xu L; Xu Y; Yuan F; Li J; Wu M; Da Z; Wei H; Zhou L; Yin S; Wu J; Lu Y; Su D; Liu Z; Liu L; Ma L; Xu X; Liu H; Ren T; Zang Y
    Clin Rheumatol; 2024 Jan; 43(1):339-347. PubMed ID: 37985533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.